Lori Lebson

538 total citations
15 papers, 436 citations indexed

About

Lori Lebson is a scholar working on Pathology and Forensic Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Lori Lebson has authored 15 papers receiving a total of 436 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pathology and Forensic Medicine, 5 papers in Molecular Biology and 4 papers in Oncology. Recurrent topics in Lori Lebson's work include Multiple Sclerosis Research Studies (6 papers), Acute Lymphoblastic Leukemia research (4 papers) and Neuroinflammation and Neurodegeneration Mechanisms (4 papers). Lori Lebson is often cited by papers focused on Multiple Sclerosis Research Studies (6 papers), Acute Lymphoblastic Leukemia research (4 papers) and Neuroinflammation and Neurodegeneration Mechanisms (4 papers). Lori Lebson collaborates with scholars based in United States, Germany and Italy. Lori Lebson's co-authors include Daniel C. Lee, Chad A. Dickey, Katharine A. Whartenby, Dave Morgan, Kevin Nash, Marcia N. Gordon, Peter A. Calabresi, Anne R. Gocke, Umesh K. Jinwal and John Koren and has published in prestigious journals such as Journal of Neuroscience, The Journal of Immunology and Neurology.

In The Last Decade

Lori Lebson

14 papers receiving 431 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lori Lebson United States 8 172 149 148 129 62 15 436
Michael Frangieh United States 7 327 1.9× 164 1.1× 148 1.0× 222 1.7× 49 0.8× 7 530
Juan Antonio García‐León Spain 14 96 0.6× 136 0.9× 203 1.4× 88 0.7× 110 1.8× 18 487
Lynn van Olst Netherlands 10 200 1.2× 142 1.0× 155 1.0× 76 0.6× 25 0.4× 13 429
Jillian C. Nissen United States 12 277 1.6× 62 0.4× 139 0.9× 180 1.4× 78 1.3× 16 497
Zhana Haimon Israel 7 304 1.8× 139 0.9× 138 0.9× 292 2.3× 43 0.7× 9 580
Emma Gerrits Netherlands 10 407 2.4× 181 1.2× 190 1.3× 166 1.3× 58 0.9× 13 568
Heike Mrowetz Austria 10 344 2.0× 194 1.3× 170 1.1× 106 0.8× 57 0.9× 16 567
Junko Miyoshi Japan 7 235 1.4× 65 0.4× 79 0.5× 138 1.1× 36 0.6× 12 377
Yang Sui Japan 8 217 1.3× 77 0.5× 132 0.9× 91 0.7× 77 1.2× 13 445
Sarah M. Carpanini United Kingdom 13 173 1.0× 177 1.2× 255 1.7× 113 0.9× 96 1.5× 18 633

Countries citing papers authored by Lori Lebson

Since Specialization
Citations

This map shows the geographic impact of Lori Lebson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lori Lebson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lori Lebson more than expected).

Fields of papers citing papers by Lori Lebson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lori Lebson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lori Lebson. The network helps show where Lori Lebson may publish in the future.

Co-authorship network of co-authors of Lori Lebson

This figure shows the co-authorship network connecting the top 25 collaborators of Lori Lebson. A scholar is included among the top collaborators of Lori Lebson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lori Lebson. Lori Lebson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Sguigna, Peter V., Rehana Z. Hussain, Kyle Blackburn, et al.. (2024). Cladribine tablets after treatment with natalizumab (CLADRINA) – rationale and design. Therapeutic Advances in Neurological Disorders. 17. 3 indexed citations
2.
3.
4.
Miravalle, Augusto, Joshua Katz, Derrick Robertson, et al.. (2021). CLICK-MS and MASTER-2 Phase IV Trial Design: Cladribine Tablets in Suboptimally Controlled Relapsing Multiple Sclerosis. Neurodegenerative Disease Management. 11(2). 99–111. 6 indexed citations
5.
Freedman, Mark S., Patricia K. Coyle, Giancarlo Comi, et al.. (2021). Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study. Multiple Sclerosis Journal - Experimental Translational and Clinical. 7(1). 2456410820–2456410820. 5 indexed citations
6.
Oh, Jiwon, Gavin Giovannoni, Dominic Jack, et al.. (2021). Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis. Multiple Sclerosis Journal - Experimental Translational and Clinical. 7(3). 3080387498–3080387498. 7 indexed citations
7.
Hersh, Carrie M., et al.. (2021). The implications of suboptimal year-1 outcomes with disease-modifying therapy in employees with multiple sclerosis. Journal of Medical Economics. 24(1). 479–486. 5 indexed citations
8.
Jones, Melina, et al.. (2013). Accelerated axon loss in MOG35-55 experimental autoimmune encephalomyelitis (EAE) in myelin-associated glycoprotein-deficient (MAGKO) mice. Journal of Neuroimmunology. 262(1-2). 53–61. 11 indexed citations
9.
Lee, Daniel C., Lori Lebson, Maj-Linda B. Selenica, et al.. (2013). Aging enhances classical activation but mitigates alternative activation in the central nervous system. Neurobiology of Aging. 34(6). 1610–1620. 100 indexed citations
10.
Gocke, Anne R., Lori Lebson, Inna V. Grishkan, et al.. (2012). Kv1.3 Deletion Biases T Cells toward an Immunoregulatory Phenotype and Renders Mice Resistant to Autoimmune Encephalomyelitis. The Journal of Immunology. 188(12). 5877–5886. 62 indexed citations
11.
Lebson, Lori, Tony J. C. Wang, Qiong Jiang, & Katharine A. Whartenby. (2011). Induction of the glucocorticoid-induced leucine zipper gene limits the efficacy of dendritic cell vaccines. Cancer Gene Therapy. 18(8). 563–570. 18 indexed citations
12.
Li, Qingyou, Lori Lebson, Daniel C. Lee, et al.. (2011). Chronological Age Impacts Immunotherapy and Monocyte Uptake Independent of Amyloid Load. Journal of Neuroimmune Pharmacology. 7(1). 202–214. 11 indexed citations
13.
Lebson, Lori, Kevin Nash, Siddharth G. Kamath, et al.. (2010). Trafficking CD11b-Positive Blood Cells Deliver Therapeutic Genes to the Brain of Amyloid-Depositing Transgenic Mice. Journal of Neuroscience. 30(29). 9651–9658. 100 indexed citations
14.
Lebson, Lori, Anne R. Gocke, Jason M. Rosenzweig, et al.. (2010). Cutting Edge: The Transcription Factor Kruppel-Like Factor 4 Regulates the Differentiation of Th17 Cells Independently of RORγt. The Journal of Immunology. 185(12). 7161–7164. 40 indexed citations
15.
Dickey, Chad A., Umesh K. Jinwal, John Koren, et al.. (2008). Aging Analysis Reveals Slowed Tau Turnover and Enhanced Stress Response in a Mouse Model of Tauopathy. American Journal Of Pathology. 174(1). 228–238. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Frangieh Breakdown of academic impact, for papers by Juan Antonio García‐León Breakdown of academic impact, for papers by Lynn van Olst Breakdown of academic impact, for papers by Jillian C. Nissen Breakdown of academic impact, for papers by Zhana Haimon Breakdown of academic impact, for papers by Emma Gerrits Breakdown of academic impact, for papers by Heike Mrowetz Breakdown of academic impact, for papers by Junko Miyoshi Breakdown of academic impact, for papers by Yang Sui Breakdown of academic impact, for papers by Sarah M. Carpanini
Rankless by CCL
2026